摘要:
A solid support for use in non-aqueous DNA-conjugated molecule reactions, wherein the support comprises a solid body formed from a plurality of polyethylene glycol units, wherein the solid body includes at least one cationic moiety.
摘要:
Compounds are provided having one of the the following structures (I) or (II): or (I) (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R3a, R3b, L1, L2, G1a, G1b, G2a, G2b and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
摘要:
The invention relates to dendritic chelated compounds, to methods for producing the same and to pharmaceutical compositions containing the same. The dendritic chelated complexes of the present invention have the following formula (I): [[MC]-En-[D]m-X1p1X2p2X3p3 X4p4]z - z B+ (I), where m is a magnetic or scintigraphic marker, C is a chelating agent of the marker M, E is a spacer, n = 0 or 1, D is compound capable of forming a dendritic structure, m is an integer equal to 1 or 2 or 4, X1 is a group increasing the complex lipophily, p1 is an integer from 0 to 12, X2 is a group increasing the complex specificity for a particular organ, p2 is an integer equal to 1 or 2 or 4, X3 is a group having a therapeutic activity, p3 is an integer equal to 0, 1, 2 or 4, X4 is a CH3 group, p4 is an integer from 0 to 12, B is a counter-ion, z is an integer equal to 0, 1, 2, 3 or 4. The invention can be used in the field of pharmacy, more precisely in medical imaging.
摘要:
Here described are compounds of formula I: wherein R1 and R2 is independently selected from a group consisting of C10 to C18 alkyl, C12 to C18 alkenyl, and oleyl group; wherein R3 and R4 are independently selected from a group consisting of C1 to C6 alkyl, and C2 to C6 alkanol; wherein X is selected from a group consisting of -CH2-, -S-, and -O- or absent; wherein Y is selected from -(CH2)n, -S(CH2)n, -O(CH2)n-, thiophene, -SO2(CH2)n-, and ester, wherein n = 1 -4; wherein a = 1 -4; wherein b=l -4; wherein c=l-4; and wherein Z is a counterion; and compounds consisting of the structure (targeting molecule)m-linker-(targeting molecule)n, wherein the targeting molecule is a retinoid or a fat soluble vitamin having a specific receptor on the target cell; wherein m and n are independently 0, 1, 2 or 3; and wherein the linker comprises a polyethylene glycol (PEG) or PEG-like molecule, as well as compositions and pharmaceutical formulations including one or both of these compounds which are useful for the delivery of therapeutic agents; and methods of using these compositions and pharmaceutical formulations.
摘要:
The present invention concerns prodrugs of mexiletine (and mexiletine's active metabolite) with amino acids or peptides and pharmaceutical compositions containing such prodrugs. Methods for providing pain relief, treating arrhythmia, decreasing the adverse GI side effects associated with mexiletine, increasing the bioavailability of mexiletine, and improving the pharmacokinetic reproducibility of mexiletine with the aforementioned prodrugs are also provided. Oligopeptides incorporating lysine or arginine residues attached directly or indirectly through a glycine residue are also described herein.
摘要:
The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing two linked iodinated phenyl groups of the general formula R-N(CO-CH2R1) -X-N(CO-CH2R1 )-R and salts or optical active isomers thereof, wherein each R1 independently denotes a hydrogen or a C1 to C4 alkoxy moiety provided that at least one R1 denotes a C1 to C4 alkoxy moiety; X denotes a C3 to C10 straight or branched alkylene moiety which may be further substituted, and each R denotes a triiodinated phenyl residue further substituted by hydrophilic moieties. The invention also relates to the use of such compounds and diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging.
摘要翻译:本发明涉及一类化合物和含有这些化合物的诊断组合物,其中化合物是含碘化合物。 更具体地说,含碘化合物是含有两个通式为RN(CO-CH 2 R 1)-XN(CO-CH 2 R 1)-R的连接的碘代苯基的化合物及其盐或光学活性异构体,其中每个R 1独立地表示氢或 C1至C4烷氧基部分,条件是至少一个R1表示C1至C4烷氧基部分; X表示可被进一步取代的C3至C10直链或支链亚烷基部分,并且每个R表示进一步被亲水部分取代的三碘代苯基残基。 本发明还涉及这种化合物和诊断组合物作为造影剂在诊断成像中,特别是在X射线成像中的用途。
摘要:
L'invention est relative à un procédé de préparation d'une combrétastatine (A) sous forme de base ou d'un sel d'addition avec un acide, consistant à coupler en présence d'une base et de T3P le sel du composé (Z)-amino de formule (I) avec un dérivé de la L-sérine doublement protégé de formule (II) dans lequel PG désigne un groupe protecteur de la fonction aminé de façon à obtenir le composé de formule (Z)-(Ib) : puis à déprotéger et ouvrir le cycle de (Z)-(Ib) en présence d'un acide de façon à obtenir la combrétastatine (A) sous forme de sel; et éventuellement à rajouter une base de façon à obtenir la combrétastatine (A) sous forme de base, le sel du composé (Z)-amino ayant été obtenu par un enrichissement du sel du composé amino de formule (III) en isomère (Z).
摘要:
La présente invention a pour objet la mise au point d'une nouvelle famille de lipides cationiques et leur utilisation comme vecteurs de délivrance in vitro , ex vivo et in vivo d'agents biologiquement actifs.
摘要:
The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.
摘要:
Midodrine hydrochloride, +/- 1-(2',5'-dimethoxyphenyl)-2-glycineamido-ethanol-(1)- HCI, is prepared from a novel intermediate, 1-(2',5'-dimethoxyphenyl)-2-azidoethanone.